A host of chemotherapeutic agents and antibiotics have been employed in the treatment of deep mycotic infections. With the exception of actinomycosis and nocardiosis the commonly employed antimicrobial agents have proved to be ineffective. In the past few years a number of new antifungal agents have received attention a s possible therapeutic drugs. Since the literature is not clear on the efficacy of these drugs, we would like to briefly review the subject and add our experiences with these agents. Recently we have extended pre-existing clinical trials1 to include a newly described antibiotic, amphotericin B. Preliminary results with this agent in the treatment of histoplasmosis and cryptococcosis are quite promising and will be presented in detail.
A host of chemotherapeutic agents and antibiotics have been employed in the treatment of deep mycotic infections. With the exception of actinomycosis and nocardiosis the commonly employed antimicrobial agents have proved to be ineffective. In the past few years a number of new antifungal agents have received attention a s possible therapeutic drugs. Since the literature is not clear on the efficacy of these drugs, we would like to briefly review the subject and add our experiences with these agents. Recently we have extended pre-existing clinical trials1 to include a newly described antibiotic, amphotericin B. Preliminary results with this agent in the treatment of histoplasmosis and cryptococcosis are quite promising and will be presented in detail.
Antecedent Therapeutic Trials
Aromatic Diamines: Elson2 in 1945 reported that certain of the diamines exerted a fungistatic effect on Blastomyces dermatitidis in vitro. Following this a series of reportsa-a appeared in the literature indicating favorable results obtained with stilbamidine and later 2-hydroxystilbamidine in the treatment of blastomycosis. Of the five cases of systemic blastomycosis treated by our group results have likewise been favorable. All of our cases received 2-hydroxy 4,4' stilbenedicarboxamide (2-hydroxystilbamidine, Merrell) intravenously in a daily dose of 225 mg. In three cases complete clearing occurred after a 30 day course of therapy. The remaining two patients required a second course before complete recovery. 598 
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In view of the remissions produced in blastomycosis, two cases of chronic progressive cavitary histoplasmosis and one with disseminated disease were treated with a similar therapeutic regime without demonstrable effect. In vitro studies7 indicate that the body fluid levels required to inhibit the growth of Histophma capsulatum f a r exceed those which can be obtained.
With the development and availability of the analog, 2 amino 4,4' stilbenedicarboximide (aminostilbamidine, Merrell) three patients with cavitary histoplasmosis were treated with 250 mg. intravenously daily for 30 to 60 days. No definite therapeutic effect could be demonstrated. Since that time a number of favorable results and failures have been reported14-la in the literature. Although we have had no experience with this drug, the apparently erratic results obtained by others and the narrow therapeutic index led us to search for a better therapeutic agent.
MRD-112:
Nystatin: In 1951 Hazen and Brown1? described an antifungal agent derived from several species of Streptomyces. This antibiotic was first called "fungicidin" but subsequently renamed nystatin (Mycostatin, Squibb).
Animal studies by Campbell1G revealed that nystatin was a n effective in vivo antifungal agent. Negligible absorption from the gastrointestinal tract precluded the use of oral nystatin in the treatment of the deep mycotic infections. Trials with a n intravenous preparation were undertaken in four patients with cavitary histoplasmosis and one with cavitary coccidioidomycosis. In four of these marked side reactions consisting of chills, fever, nausea and vomiting prevented a full course of therapy. One case with cavitary histoplasmosis received 200,000 units daily for 62 days without demonstrable therapeutic or toxic effect.
Amebacide: In 1952 the Eli Lilly Co. called our attention to a chemical compound 1, 2 Bis para (n-hexyl methylaminomethyl) phenoxy ethane dihydrochloride (amebacide CT 686). I n vitro studiesIo revealed this to have considerable activity against a variety of fungi. Since this compound was relatively soluble in water, therapeutic trials with an oral preparation were undertaken. Fourteen cases of cavitary histoplasmosis received oral doses ranging from 45 to 300 mg. daily for a period of three months. Results were disappointing; in only one instance was it thought that the drug exhibited some beneficial effect on the patient's clinical course.
Therapeutic Trials with Amphotericin B Recently members of the Squibb Institute of ~e d i c a l
Research have isolated and described a new antifungal antibiotic derived from a soil Strept o m y c e~.~~~~~ Studies by this group indicate that amphotericin B is a weak base and is amphoteric a s demonstrated by its greater solubility in acidic o r basic aqueous alcoholic solvents. While the exact chemical structure of this compound is not known its molecular formula has been established a s C,, Hi3 N020.22 Ultraviolet absorption maxima indicate that there is a conjugated haxaenic or heptaenic system in amphotericin B.
I n vitro studies by Gold, Stout, Pagano and Donovick20 reveal that amphotericin B does not have antibacterial activity but is effective in inhibiting the growth of the yeast and yeastlike fungi. Recent in witro stud- Cryptococcosis: All the cases in this series presented clinical evidence of meningitis and Ctyptococcus neofomcans was readily recovered from the spinal fluid. In each instance pathogenicity was confirmed by intracerebral mouse inoculation. Table I outlines the pre-treatment status and cultures, the therapeutic regime and response of these patients. It should be noted that both patients who failed to improve were in extremis and expired shortly after instituting therapy. Although Case 2 received oral therapy only, she improved and has been symptom free for one year. It is possible that she was undergoing spontaneous remission when-therapy was started. In each instance where intravenous therapy was employed the patients were followed with spinal fluid cultures performed a t weekly intervals. Despite repeated cultures, in no instance was the organism recovered after two weeks or more of intravenous therapy. Case 4 had, in addition to meningitis, several cutaneous lesions of three months duration due to C.
neofomnans. Figure 2 presents the rather dramatic healing of one of these leaions while under therapy.
In all but one case the cerebrospinal fluid cell count, sugar and protein have reverted to normal. In the exception (Case 5) gradual but progressive reduction in cell counts and protein was noted but without completely re- turning to normal during the short period of follow up. Case 6 is presented here briefly to illustrate the response noted.
Case 6 : * This 31 year old white woman was admitted to the hospital for the fourth time on December 27, 1956 with the chief complaint of severe headaches. She dated the onset of illness to May 1956 when she noted the sudden onset of severe generalized headaches, stiff neck and low grade fever. In the succeeding four months she was hospitalized on three occasions for persistence of these symptoms. In August 1956, she noted the onset of a constant "roaring" sensation in both ears and brief episodes of visual and auditory hallucinations. At this time it was observed that there was some "blurring" of the optic discs and the cerebrospinal fluid pressure was found to be consistently about 400 ml. of water. Ventriculograms a t this time were interpreted as normal. Because of the unremitting headaches and frequent episodes of vomiting, spinal tap was performed every week to reduce the cerebrospinal fluid pressure. Despite the frequent spinal taps severe headaches as well as low grade temperature persisted. Approximately one month prior to admission she began having transitory attacks during which time she would develop numbness of the lower half of her face and the buccal mucosa on the right side. These attacks were associated with considerable difficulty in speaking intelligibly.
Physical examination on this admission was essentially negative except for bilateral "blurring" of the optic discs and questionable left facial weakness. She was seen by an ophthalmologist who felt that this blurring did not represent papilledema.
A spinal tap performed the day after admission revealed an opening pressure of 280 ml. of water. On examination, the fluid was found to contain 120 white blood cells per mm? (98 per cent lymphocytes), 29 mg. per cent sugar and 144 mg. per cent total protein. Routine bacterial cultures and cultures for Mycobacten'um tuberculosis were negative. Cultures for fungi were positive for C. neoformans. Hematopoietic, renal and hepatic studies and chest roentgenogram were considered within normal limits.
On January 7, 1957 she was started on intravenous amphotericin B., 50 mg. daily, which was administered for 13 days. This was followed by 100 mg. every other day for an additional 27 doses. On the 10th day of therapy, a spinal tap revealed the following: opening pressure 250 ml. of water, 29 white blood cells (100 per cent lymphocytes), sugar 47 mg. per cent and total protein 70 mg. per cent. Culkures and intracerebral inoculation of spinal fluid were negative for C. neofomtans and remained so in nine succeeding spinal taps over the next five months. Following the initial drop in cerebrospinal fluid protein and cells and the rise in sugar only minor changes were noted over the next two months. Three weeks after the completion of intravenous therapy the cerebrospinal fluid pressure, cell counts, protein and sugar were all within normal limits.
After one week of therapy she was essentially afebrile and asymptomatic exce t for occasional headaches. By the third week the headaches had almost completefy disappeared. Five months after instituting therapy she was asymptomatic.
Histoplasmosis: As a result of our interest in this disease and our geographical location suitable cases with this entity were most readily available for therapeutic trials. In a n effort to critically interpret our results in the treatment of histoplasmosis we will consider separately the three forms of the disease we have treated. All cases selected for trials were proved by isolation of the fungus by culture. Division of cases into the various classifications is based on criteria previously outlined by Furco-1 ) Progressive Disseminated Histoplasmosis: Six cases with this almost universally fatal entity received amphotericin B. The first two received only oral drug and in both instances temporary clinical improvement and negative cultures were obtained while under active therapy. Both patients relapsed approximately one month after the therapy was stopped. The remaining four received intravenous therapy a s outlined in Table 11 . While two of them expired, only three doses were administered before their de-*Case included with permission of Dr. Martin FitzPatrick, of the University of Kansas Medical Center, who will report the case in detail. Figure 4A ). At this time a tentative diagnosis of sarcoidosis was made and he was started on prednisone. During the following month he remained afebrile and appeared to improve clinically. Shortly thereafter fever returned and he began a rapid downhill course. On September 17, 1956, he was readmitted to the hospital in a moribund state. Physical examination a t this time revealed a chronically ill, febrile, disorientated elderly man with hepatosplenomegaly. A roentgenogram of the chest showed a questionable increase in pulmonary infiltrations. Cultures of the bone marrow and sputum yielded H. capsulatum.
A two months course of intravenous amphotericin B supplemented with oral drug, as outlined in Table 11 , was started on September 19, 1956 . Ten days after instituting therapy, cultures for H. capsulatum were found to be negative a s have all subsequent cultures. A chest roentgenogram one month later demonstrated "marked clearing" ( Figure 4B ). During this period he became afebrile, and in succeeding months the hepatosplenomegaly slowly regressed although the tip of the spleen remains palpable. He has remained afebrile and continues to be well after eight months. 
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2) Chronic Progressive Pulmonary Histop2asmosis: Six patients who were classified in this category were selected for therapeutic trials with oral and intravenous amphotericin B. Of these, five had cavitary disease and the remaining case had long standing apical disease without cavitation. Only cases in which H. capsulatum has been repeatedly isolated from the sputum were selected for study. In an effort to minimize the possible effect of bed rest and general supportive measures all cases were observed for two to three months before therapy was instituted. Only one (Case 17) had significant clinical and x-ray film improvement on bed rest alone. Drug therapy was withheld in this case until his clinical status and x-ray films were stable. The problems of evaluation of therapy on a short term basis for this type of disease are comparable to those with advanced pulmonary tuberculosis. The criteria used in evaluating response to therapy were: (1) Changes in clinical status, (2) X-ray changes, (3) Complement fixation titer changes, (4) Conversion of sputum cultures. A summary of the clinical and laboratory data on these patients is presented in Table 111 . It should be noted that cases 13 and 14 received largely prolonged oral therapy. Both of these cases showed clinical improvement and slight to moderate x-ray film change but sterilization of the sputum was obtained in case 13 only. The remaining four cases received oral drug supplemented by significant amounts of intravenous amphotericin. B. In all these cases clinical and x-ray improvement as well as sterilization of the sputa was accomplished. In only one instance, however, was cavity closure noted. Figure 5 demonstrates the typical pulmonary lesions and their response to amphotericin B. Case 15 is presented in detail to point out the similarity of this entity to tuberculosis and its response to therapy. 
B. H.
Poor and bilateral bronchial washings were negative on smear and culture for M. tubmawlobis. Two s uta and the bronchial washings were cultured for fungi and all were positive for 8. capm~=tum.
Atter three months of bed rest and supportive therapy no significant change was noted and the patient was started on combined oral and intravenous amphotericin B a s outlined in Table 111 . Under therapy he has shown a good clinical response with weight gain, disappearance of cough and marked reduction in sputum. Shortly after instituting therapy, H. capsulatum could no longer be isolated from the sputum despite repeated attempts. Figure 6 demonstrates the improvement on x-ray film after three months of amphotericin B.
3) Severe Acute Pdmomry Histoplasmosis: In light of the previously promising results a case with severe "epidemic" histoplasmosis was selected to observe the effect of the drug on the acute form of the disease.
The prompt clinical response and fall in temperature and rapid clearing: on x-ray film coincident with administration of the intravenous drug lead! us to believe that they are causally related. It should be cautioned that: the course is difficult to interpret since recovery is the rule in this form of histoplasmosis. On the basis of past experience it is our opinion that this illness was significantly shortened. Persistence of these symptoms despite broad spectrum antibiotics led to his hospitalization two days later. A chest roentgenogram taken shortly after admission revealed a "diffuse" mottling throughout both lung fields ( Figure 7A ), whereas, a roentgenogram on admission was essentially negative. On the basis of clinical and epidemiological evidence a tentative diagnosis of acute "epidemic" histoplasmosis was made. H. c a p suhtum was subsequently isolated from gastric washings taken shortly after admission.
His course during the first six days of hospitalization was characterized by frequent shaking chills, drenching night sweats, fever to 104" F. and marked fatigue. On the fourth day moderate dyspnea was noted. By the seventh hospital day his general clinical condition had deteriorated and oral amphotericin B, 4 grams daily in divided doses, was given. After two days a t this dosage level without demonstrable effect, the dosage was raised to 9.6 grams. Two days later the patient's condition appeared critical and intravenous therapy was instituted. vol. XXxII
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strating the rather dramatic drop in temperature coincident with the administration of the drug intravenously. After seven days i t was decided to alter the therapeutic regime to every other day. I t will be noted that with the temporary discontinuance of the drug there was a rise in temperature which again fell after therapy was reinstituted. His clinical response and clearing of pulmonary lesions paralleled his temperature curve (Figure 7B ).
Dosage and Administration:
The oral preparation used in these studies was administered as 200 mg. tablets of crystalline amphotericin B. Administration in dosages up to 8 grams daily presented no problem, however, poor absorption from the gastrointestinal tract makes this a questionable route of administration. Temporary improvement of several cases while under oral therapy indicate that this drug even in extremely low levels exerts some in vivo fungistatic effect.
Intravenous amphotericin B used in this series of cases was administered as a colloidal suspension (Estimated particle size 3 microns). The desired dose of amphotericin B was suspended in 5 per cent aqueous solution of dextrose in concentration of 1 mg. of drug per 5-10 cubic centimeters of water. Administration of the drug over a six hour period greatly reduced the incidence of side reactions. Studies by Louria et alsZ5 indicate that amphotericin B serum levels of 0.7 to 1.5 mcg./ml. offered excellent protection and resulted in negative cultures of mice experimentally infected with H. capsulatum or C. neoformans. Using a modification of the bioassay technique described by Littman27 comparable levels were obtained in humans receiving a dose equivalent to 1 mg./kg. body weight. Levels above 0.1 mcg./ml. were found to persist for approximately 18 hours. One case receiving 1.7 mg./kg. maintained a serum level of 0.3 mcg./ml. for 30 hours after the drug was administered. From these data it is evident that a dose equivalent to a t least 1 mg./kg. body weight is desirable. The persistence of the drug in the serum with higher doses indicates that such doses could be given every other day. Despite adequate amphotericin B serum levels, measurable spinal fluid levels ( > .06 mcg./ml.) were not detected among the spinal fluids assayed.
Toxic Manifestations and Side Reactions:
No evidence of either acute or chronic toxicity was noted in any of the patients receiving the oral form of amphotericin B. Several of these patients have received a total dose in excess of 1000 grams without ill effect. In several cases receiving intravenous therapy supplemented by oral drug, minor upper gastrointestinal symptoms and headache were noted.
The colloidal suspension of amphotericin B administered intravenously to the cases in this series resulted in several rather consistent undesirable side reactions. In almost every instance, shaking chills followed by a "spike" in temperature, during administration of the drug, was noted. It has been our experience that careful premeditation with antihistaminics and antipyretics will reduce these to a minimum. Chemical phlebitis was troublesome but its incidence was not prohibitive if the drug was given slowly over a six hour period. In several instances the drug infiltrated into the surrounding subcutaneous tissues. Although this resulted in mild discomfort and redness a t the site, no serious complication resulted.
Repeated hematopoetic, hepatic and renal function studies failed to show any evidence of toxicity. In only one (Case 4) was there evidence of possible toxic effect. In this case a transient rise in the blood urea nitrogen followed a dose of amphotericin B equivalent to approximately 1.4 mg./kg. This may have been related to persistent vomiting due to increased intra-cranial pressure and resultant dehydration. Following rehydration the blood urea nitrogen returned to normal. In this same patient the drug was discontinued earlier than planned because of the development of generalized pruritus.
Although only one of our cases showed a rise in the blood urea nitrogen, this rise has been noted by others using amphotericin B.28 This finding was not accompanied by any other signs of renal toxicity and was only associated with higher doses of intravenous amphotericin B. Renal function, therefore, should be closely watched in those patients receiving doses above 1 mg./kg. of body weight.
Discussion
The present study conducted over the past several years was designed to "screen" promising antifungal agents. Both in vitro studies and clinical trials were employed to evaluate the therapeutic potentialities and toxicity of these agents. Clinical trials conducted on 38 patients with cryptococcal meningitis or progressive histoplasmosis with 2 hydroxystilbamidine, aminostilbamidine, MRD-112, mycostatin, and amebacide Among the patients treated with amphotericin B preliminary results were dramatic with both clinical improvement and cultural conversion. Poor absorption from the gastrointestinal tract make the present oral preparation of only questionable value. Studies are now under way to find some means of enhancing absorption from the gastrointestinal tract. The intravenous preparation is moderately well accepted by the patient in its present state and "adequate" blood levels are easily obtainable. The problems of short follow-up periods and spontaneous remissions even among those forms of mycotic infections generally considered fatal must be considered. This may well account for the response noted in any single case treated with amphotericin B. I t is, however, unlikely that this can explain the consistently favorable response and conversion of cultures in all patients receiving significant amounts of intravenous drug. I t is difficult to explain the dramatic response obtained in cryptococcal meningitis in light of our inability to demonstrate drug levels in the cerebro-spinal fluid. I t may be only small amounts of drug are necessary and the bioassay technique employed does not detect such levels.
In vitro studies and clinical trials now under way in patients with blastomycosis and coccidioidomycosis indicate that this agent may well be a "broad spectrum" antifungal antibiotic.
The moderate x-ray improvement noted among those with chronic progressive cavitary histoplasmosis is not surprising if one considers the underlying pathologic changes. The fact that marked reduction in sputum and cultural conversion was attained is considered to be a highly significant finding. Recently we have followed some 30 cases of chronic progressive pulmonary histoplasmosis with frequent cultures for varying periods up to two years. Of the 300 cultures performed, H. capsulatum was recovered in 75 per cent of the specimens.29 I t appears to us that the therapy of histoplasmosis with amphotericin B may well be in the same stage as that of tuberculosis in the early streptomycin era. Combined drug therapy may be the solution to the problem.30 Although surgery has been of definite value in appropriate cases, fear of complications with an organism resistant to therapy has been a major deterrent to this approach. The availability of a specific therapeutic agent will undoubtedly make this approach more feasible. Se obtuvieron respuestas favorables en la blastomicosis generalizada usando 2 hidroxi 4, 4 estibenedicarboxamida.
Los resultados obtenidos preliminarmente con nuevo antibibtico, amfotericina B (Fungizona Squibb), en 19 casos de meningitis de criptococos y en histoplasmosis se relatan. Los enfermos tratados con anfotericina B demostraron mejoria clinica y radiol6gica. Los especimenes clinicos viraron a la negatividad despuks del tratamiento con amfotericina B. Este antibi6tico demostr6 ser relativamente no t6xico y ofrece la primera esperanza de una terapkutica especifica para estas afecciones mic6sicas. RESUME Six medications antimycosiques, efficaces in vitro furent essayks cliniquement chez 60 malades atteints d'infections mycosiques skvhres progressives, pour kvaluer leur effet thkrapeutique et leur toxicitii. On ne put mettre en kvidence aucun effet thkrapeutique sur I'histuplasmose ou la cryptococcose pendant ces essaiq tant avec le B diethyl-aminoethyl fencolate (MRD.112, Merrell), le 2 hydroxy 4, 4' stilbenedicarboxamide (2-hydroxyzltilbamidine, Merrell) le 2 amino 4,4' stilbenedicarboxamide (aminostilbamidine, Merrell) la "nystatine" (mycostatin, Squibb) qu'avec le 1, 2 bis para (n-hexyl methylaminomethyl) phenoxy ethane dihydrochloride 
